



**HAL**  
open science

## Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency

Julien Cottineau, Molly C. Kottemann, Francis P. Lach, Young-Hoon Kang, Frederic Vely, Elissa K. Deenick, Tomi Lazarov, Laure Gineau, Yi Wang, Andrea Farina, et al.

### ► To cite this version:

Julien Cottineau, Molly C. Kottemann, Francis P. Lach, Young-Hoon Kang, Frederic Vely, et al.. Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. Journal of Clinical Investigation, 2017, 127 (5), pp.1991-2006. 10.1172/JCI90727 . hal-01765083

**HAL Id: hal-01765083**

**<https://amu.hal.science/hal-01765083>**

Submitted on 29 Oct 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

# Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency

Julien Cottineau, ... , Agata Smogorzewska, Emmanuelle Jouanguy

Inborn errors of DNA repair or replication underlie a variety of clinical phenotypes. We studied 5 patients from 4 kindreds, all of whom displayed intrauterine growth retardation, chronic neutropenia, and NK cell deficiency. Four of the 5 patients also had postnatal growth retardation. The association of neutropenia and NK cell deficiency, which is unusual among primary immunodeficiencies and bone marrow failures, was due to a blockade in the bone marrow and was mildly symptomatic. We discovered compound heterozygous rare mutations in Go-Ichi-Ni-San (GINS) complex subunit 1 (*GINS1*, also known as *PSF1*) in the 5 patients. The GINS complex is essential for eukaryotic DNA replication, and homozygous null mutations of GINS component–encoding genes are embryonic lethal in mice. The patients' fibroblasts displayed impaired GINS complex assembly, basal replication stress, impaired checkpoint signaling, defective cell cycle control, and genomic instability, which was rescued by WT *GINS1*. The residual levels of GINS1 activity reached 3% to 16% in patients' cells, depending on their *GINS1* genotype, and correlated with the severity of growth retardation and the in vitro cellular phenotype. The levels of GINS1 activity did not influence the immunological phenotype, which was uniform. Autosomal recessive, partial GINS1 deficiency impairs DNA replication and underlies intra-uterine (and postnatal) growth retardation, chronic neutropenia, and NK cell deficiency.

# Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency

Julien Cottineau,<sup>1,2</sup> Molly C. Kottemann,<sup>3</sup> Francis P. Lach,<sup>3</sup> Young-Hoon Kang,<sup>4</sup> Frédéric Vély,<sup>5,6</sup> Elissa K. Deenick,<sup>7</sup> Tomi Lazarov,<sup>8</sup> Laure Gineau,<sup>1,2</sup> Yi Wang,<sup>1,2</sup> Andrea Farina,<sup>4</sup> Marie Chansel,<sup>2,9</sup> Lazaro Lorenzo,<sup>1,2</sup> Christelle Piperoglou,<sup>5,6</sup> Cindy S. Ma,<sup>7</sup> Patrick Nitschke,<sup>2,10</sup> Aziz Belkadi,<sup>1,2</sup> Yuval Itan,<sup>11</sup> Bertrand Boisson,<sup>1,2,11</sup> Fabienne Jabot-Hanin,<sup>1,2</sup> Capucine Picard,<sup>1,2,11,12,13</sup> Jacinta Bustamante,<sup>1,2,11,12</sup> Céline Eidenschenk,<sup>1,2</sup> Soraya Boucherit,<sup>1,2</sup> Nathalie Aladjidi,<sup>14</sup> Didier Lacombe,<sup>15</sup> Pascal Barat,<sup>16</sup> Waseem Qasim,<sup>17</sup> Jane A. Hurst,<sup>18</sup> Andrew J. Pollard,<sup>19</sup> Holm H. Uhlig,<sup>19,20</sup> Claire Fieschi,<sup>21,22</sup> Jean Michon,<sup>23</sup> Vladimir P. Bermudez,<sup>4</sup> Laurent Abel,<sup>1,2,11</sup> Jean-Pierre de Villartay,<sup>2,9</sup> Frédéric Geissmann,<sup>8</sup> Stuart G. Tangye,<sup>7</sup> Jerard Hurwitz,<sup>4</sup> Eric Vivier,<sup>5,6</sup> Jean-Laurent Casanova,<sup>1,2,11,13,24</sup> Agata Smogorzewska,<sup>3</sup> and Emmanuelle Jouanguy<sup>1,2,11</sup>

<sup>1</sup>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France. <sup>2</sup>Paris Descartes University, Imagine Institute, Paris, France. <sup>3</sup>Laboratory of Genome Maintenance, The Rockefeller University, New York, New York, USA. <sup>4</sup>Molecular Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. <sup>5</sup>Aix Marseille University, CNRS, INSERM, CIML, Marseille, France. <sup>6</sup>Assistance Publique-Hôpitaux de Marseille, Hôpital de la Conception, Service d'Immunologie, Marseille, France. <sup>7</sup>Immunology Division, Garvan Institute of Medical Research, and St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia. <sup>8</sup>Centre for Molecular and Cellular Biology of Inflammation (CMCBI), King's College London, London, United Kingdom. <sup>9</sup>Laboratory of Genome Dynamics in the Immune System, INSERM U1163, Paris, France. <sup>10</sup>Bioinformatics Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Hospital for Sick Children, Paris, France. <sup>11</sup>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York, USA. <sup>12</sup>Center for the Study of Primary Immunodeficiencies and <sup>13</sup>Pediatric Hematology-Immunology Unit, AP-HP, Necker Hospital for Sick Children, Paris, France. <sup>14</sup>Pediatric Hemato-Oncology Unit, Bordeaux Hospital, Bordeaux, France. <sup>15</sup>Bordeaux University, EA4676, Laboratoire de Maladies Rares: Génétique et Métabolisme (MRGM), and Centre Hospitalier Universitaire (CHU) de Bordeaux, Medical Genetics, Bordeaux, France. <sup>16</sup>Pediatric Endocrinology and Diabetology Unit, Clinical Investigation Center (CIC 05), Bordeaux Hospital, Bordeaux, France. <sup>17</sup>Molecular and Cellular Immunology, Institute of Child Health and Great Ormond Street Hospital, London, United Kingdom. <sup>18</sup>North East Thames Genetics Service, Great Ormond Street Hospital, London, United Kingdom. <sup>19</sup>Department of Paediatrics, University of Oxford, Children's Hospital, Oxford, United Kingdom. <sup>20</sup>Translational Gastroenterology Unit, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom. <sup>21</sup>Adult Immunopathology Unit, AP-HP, Saint-Louis Hospital, Paris, France. <sup>22</sup>Paris Diderot University, Paris, France. <sup>23</sup>Department of Pediatric Oncology, Institut Curie, Paris, France. <sup>24</sup>Howard Hughes Medical Institute, New York, New York, USA.

**Inborn errors of DNA repair or replication underlie a variety of clinical phenotypes. We studied 5 patients from 4 kindreds, all of whom displayed intrauterine growth retardation, chronic neutropenia, and NK cell deficiency. Four of the 5 patients also had postnatal growth retardation. The association of neutropenia and NK cell deficiency, which is unusual among primary immunodeficiencies and bone marrow failures, was due to a blockade in the bone marrow and was mildly symptomatic. We discovered compound heterozygous rare mutations in Go-Ichi-Ni-San (GINS) complex subunit 1 (*GINS1*, also known as *PSF1*) in the 5 patients. The GINS complex is essential for eukaryotic DNA replication, and homozygous null mutations of GINS component-encoding genes are embryonic lethal in mice. The patients' fibroblasts displayed impaired GINS complex assembly, basal replication stress, impaired checkpoint signaling, defective cell cycle control, and genomic instability, which was rescued by WT *GINS1*. The residual levels of GINS1 activity reached 3% to 16% in patients' cells, depending on their *GINS1* genotype, and correlated with the severity of growth retardation and the in vitro cellular phenotype. The levels of GINS1 activity did not influence the immunological phenotype, which was uniform. Autosomal recessive, partial GINS1 deficiency impairs DNA replication and underlies intra-uterine (and postnatal) growth retardation, chronic neutropenia, and NK cell deficiency.**

## Introduction


NK lymphocytes are innate lymphoid cells (ILCs) that contribute to protective immunity to viruses in the course of experimental infection in inbred mice (1, 2). In humans, their function remains unclear,

### ► Related Commentary: p. 1616

**Authorship note:** M.C. Kottemann, F.P. Lach, Y.H. Kang, and F. Vély contributed equally to this work. J. Hurwitz and E. Vivier contributed equally to this work. E.K. Deenick, T. Lazarov, L. Gineau, and Y. Wang contributed equally to this work. J.L. Casanova, A. Smogorzewska, and E. Jouanguy contributed equally to this work.

**Conflict of interest:** The authors have declared that no conflict of interest exists.

due to the rarity of well-documented inherited disorders involving a selective and complete lack of NK cells (3, 4). An autosomal recessive (AR) and partial deficiency of mini-chromosome maintenance 4 (MCM4) was recently reported in consanguineous kindreds (5, 6). All patients displayed intra- and extrauterine growth retardation, adrenal insufficiency, and a selective lack of CD56<sup>dim</sup> NK cells. The occurrence of unusually severe but poorly characterized viral infections in some of these patients suggested that human NK cells might be essential for host defense, at least against some viruses, under conditions of natural infection (7). These patients had normal numbers of other leukocyte subsets, including T and B lymphocytes, which apparently functioned normally. However, subtle functions of leukocytes or non-hematopoietic cells might be altered and have contributed to the observed viral diseases.




**Figure 1. NK cell and neutrophil deficiency.** (A) Representative flow cytometry plots of peripheral total NK cells in PBMCs from a travel control and 4 patients. (B) Quantification, by flow cytometry, of peripheral total, CD56<sup>bright</sup>, and CD56<sup>dim</sup> NK cells, in the travel controls and patients (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ; 1-way bidirectional ANOVA). Het, heterozygote. (C) NK cell expansion upon cytokine stimulation was assessed by culture of PBMCs with complete medium supplemented or not with IL-2 (100 U/ml) or IL-15 (10 ng/ml) for 3.5 days. (D) Quantification, by flow cytometry, of peripheral total ILC and ILC1, ILC2, and ILC3 subsets in CD45<sup>+</sup> PBMCs, MAIT (CD3<sup>+</sup>V $\alpha$ 7.2<sup>+</sup>CD161<sup>hi</sup>) cells and NKT (CD3<sup>+</sup>V $\alpha$ 24<sup>+</sup>V $\beta$ 11<sup>+</sup>) cells in the travel controls and patients. ns, not significant. (E) Neutrophil counts of 4 patients. (F) Analysis of neutrophil precursors in the bone marrow of 4 patients. Patient P5 was treated by G-CSF.

Unexpectedly, we found that maturation of CD56<sup>bright</sup> NK cells into CD56<sup>dim</sup> NK cells was highly dependent on MCM4 and, therefore, probably dependent on cell proliferation (5). We pursued the genetic dissection of human inborn errors of NK cells by investigating two French sisters (born to unrelated parents), who, as we previously reported, displayed intrauterine growth retardation, neutropenia, and a low NK cell count (8). We also previously described a possible mechanism of NK cell deficiency (NKD) in these siblings, associated with impaired IL-2-dependent survival of T lymphocytes (9). In the absence of candidate gene and linkage information, we took advantage of whole exome sequencing (WES) to search for the underlying genetic etiology (10). We report here the discovery and characterization of compound heterozy-

gous mutations of *GINS1* in these two sisters, and in three other unrelated patients with similar clinical and immunological phenotypes who were subsequently recruited. Interestingly, although MCM4 and *GINS1* are functionally related, the two corresponding deficits only partly overlap biologically and clinically.

## Results

**Clinical and immunological features of the patients.** The clinical features of the 5 patients from 4 kindreds studied are described in Methods and in the supplemental material (Supplemental Figures 1-3 and Supplemental Tables 1 and 2; supplemental material available online with this article; <https://doi.org/10.1172/JCI90727DS1>). Briefly, the patients presented with growth retar-










**Figure 2. Identification of *GINS1* mutations.** (A) Pedigrees of the 4 families, showing allele segregation. The index case is indicated by an arrow, and "E?" indicates an unknown genotype. The age of each patient is indicated in parentheses. (B) Schematic diagram of the structure of the *GINS1* cDNA, consisting of 7 exons, indicating the positions of mutations. The arrows show the primers used for cDNA amplification. Electrophoresis of PCR products from *GINS1* cDNA for a control (C+), P2, P2's father (F), P2's mother (M), P3, P4, and P5. Ex1, exon 1. (C) Schematic diagram of the relative expression levels of each allele corresponding to the various genotypes as assessed by cloning of the cDNA molecules from patient fibroblasts.

dation (intra- and extrauterine) and mild facial dysmorphism, except patient 4 (P4; no extrauterine growth retardation), together with infections with viruses but also some documented cases of bacterial infection; P2 had osteosarcoma; P3 presented with protein-losing enteropathy, hypothyroidism, and some features of premature aging; P5 had autoimmune hemolytic anemia and glaucoma. During the first 3 years of life, the two patients tested (P2 and P3) displayed low counts of blood T cells, especially CD8<sup>+</sup> T cells. The patients had otherwise low or normal numbers of circulating T and B lymphocytes (except P3, who had lower numbers), and normal proportions of naive and memory CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes, Th lymphocyte subsets, and  $\gamma\delta$ -T lymphocytes (Supplemental Figure 3, A-C). There were respective increases and decreases in proportions of naive and memory B cell subsets, but the frequency of memory B cells that underwent class switching in vivo was normal (Supplemental Figure 3D). Proliferation of T lymphocytes from all patients in vitro was slightly decreased in

response to stimulation with mitogenic phytohemagglutinin (PHA), and low but not abolished in response to recall antigens (Supplemental Table 2). Serum IgA levels were high, IgM levels were low, and IgG levels were low or in the normal range (Supplemental Figure 2D). Moreover, all patients displayed an almost complete lack of circulating NK cells, in terms of both absolute numbers (1 to 6/mm<sup>3</sup>, for a norm above 100/mm<sup>3</sup>) and proportions of lymphocytes (0.1% to 0.5%, for a norm above 5%) (Figure 1, A and B, and Supplemental Table 3). We further investigated the phenotype of the few NK cells in the patients' blood. In contrast to observations for patients with partial MCM4 deficiency, all patients tested here had very low proportions of both the CD56<sup>bright</sup> and CD56<sup>dim</sup> subsets (Figure 1B). In addition, after 4 days of IL-2 or IL-15 activation of peripheral blood mononuclear cells (PBMCs) in vitro, no increase in the proportion of NK cells (0.1%–0.2% to 0.1%–0.2%) was observed with respect to controls (0.4% to 4%) (Figure 1C), suggesting that their NK cell deficiency could not be overcome by cytokine treatment. We also investigated other circulating ILCs and invariant T lymphocyte subsets in 3 patients. The numbers of all circulating ILCs were low in P4 and P5, while P2 had low ILC2 and ILC3 levels but normal numbers of ILC1 cells (Figure 1D). P2, P3, and P4 also had decreased proportions of mucosal-associated invariant T (MAIT) and NKT cells (Figure 1D). Chronic neutropenia was noted in all these patients, from infancy onward (Figure 1E). The oxidative burst of P2 neutrophils was normal, as measured by hydrogen peroxide production in response to PMA (Supplemental Figure 3E). All other myeloid cells, including the plasmacytoid DC (pDC), myeloid DC (mDC), and monocyte subsets, were present at normal levels (Supplemental Figure 3F). We investigated whether neutropenia was due to a central or peripheral event by analyzing bone marrow aspirates. As shown in Figure 1F, the proportion of myeloblasts was normal in all patients. However, promyelocyte proportions were high, and metamyelocytes and neutrophils were reduced. Interestingly, treatment with granulocyte colony-stimulating factor (G-CSF) restored the numbers of both metamyelocytes and mature neutrophils (Figure 1F), suggesting that there might be an imbalance between proliferation and apoptosis that could be overcome functionally. This is consistent with both the virtual lack of clinical signs normally associated with chronic neutropenia in these patients and the normal neutrophil counts occasionally measured in the course of bacterial infection. The similarity in clinical and immunological phenotypes between these 5 patients and MCM4-mutated patients suggested that they might have a genetic disease due to mutations in a gene related to *MCM4* or involved in DNA replication.

*Compound heterozygous GINS1 mutations in kindred A.* We investigated siblings P1 and P2 by WES (Supplemental Table 4). We found 15 homozygous and 452 heterozygous coding variants common to both sisters that had not previously been reported at a minor allele frequency (MAF) >1% in any database (1000 Genomes, <http://www.internationalgenome.org>; HapMap, <http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html>; dbSNP, <https://www.ncbi.nlm.nih.gov/projects/SNP/>) or in our

**A****B****C****D****E****F****G**


**Figure 3. The GINS1 mutants are associated with CMG complex loss of function or instability.** (A) Western blot analysis of total protein extracts from HEK293T cells expressing *GINS1* cDNAs. Cells were not transfected (NT), mock transfected (MO), or transfected with pCMV6 empty (EV), pCMV6 *GINS1* WT-Flag (WT), pCMV6 *GINS1* R83C-Flag (R83C), pCMV6 *GINS1* delEx1-Flag ( $\Delta$ E1), or pCMV6 *GINS1* C152Y-Flag (C152Y), with antibodies against Flag-tag and *GINS1*. An antibody against  $\alpha$ -tubulin was used as a loading control. (B) Western blot analysis of total protein extracts from HEK293T cells not transfected, mock transfected, or transfected with pCMV6 empty vector (EV), pCMV6 *GINS1* WT- or  $\Delta$ E1-Flag (WT,  $\Delta$ E1), pCMV6 *GINS1* WT- or  $\Delta$ E1-ATG1-Flag (WT- or  $\Delta$ E1-ATG1), pCMV6 *GINS1* WT or  $\Delta$ E1-ATG2-Flag (WT- or  $\Delta$ E1-ATG2), pCMV6 *GINS1* WT or  $\Delta$ E1-ATG3-Flag (WT- or  $\Delta$ E1-ATG3), pCMV6 *GINS1* WT or  $\Delta$ E1-ATG1+2+3-Flag (WT- or  $\Delta$ E1-ATG1,2,3) vectors. An antibody against  $\alpha$ -tubulin was used as a loading control. (C) Western blot analysis of *GINS1* expression on total protein extracts from patient and control E6/E7-fibroblasts. An antibody against GAPDH was used as a loading control. (D) Western blot analysis of *GINS2*, *GINS3*, *GINS4*, and *MCM4* in total protein extracts from patient and control E6/E7-fibroblasts. An antibody against GAPDH was used as a loading control. (E) Western blot analysis of *GINS1* and *GINS3* expression in total protein extracts from control and P2 E6/E7-fibroblasts lentiviral transduced by empty vector (EV), *GINS1*-WT (WT), *GINS1*-R83C (R83C), or *GINS1*- $\Delta$ E1 ( $\Delta$ E1) or not transduced (NT). An antibody against GAPDH was used as a loading control. Results in A–E are representative of 3 independent experiments. (F) Total protein extracts from HeLa cells transfected with pIRESpuroHF-*GINS1* WT or mutant constructs (R83C,  $\Delta$ E1, C152Y) encoding N-terminally His<sub>6</sub>-Flag<sub>2</sub>-tagged proteins were subjected to immunoprecipitation with an antibody against the Flag tag, in the presence (+Flag) or absence of the 3XFlag peptide. Western blotting was performed with antibodies against the Flag tag, *GINS3*, and *GINS4*. Results are representative of 4 independent experiments. (G) Left: Purification of the CMG complex from Sf9 insect cells with viruses expressing the 11 CMG subunits, including *GINS1* WT or C152Y, as described in Methods. Gradient fractions were subjected to SDS-PAGE separation followed by silver staining: 5  $\mu$ l for *GINS1* WT and 15  $\mu$ l for *GINS1* C152Y. Right: The peak fractions of both CMG (WT or C152Y) purification (5  $\mu$ l fraction 7) were subjected to SDS-PAGE separation. Results are representative of 2 independent experiments.

own database of 3,000 patients with various infectious diseases (Supplemental Table 5). The most striking candidates were heterozygous variants of *GINS1*. This gene is functionally related to *MCM4* (11). *GINS1* (also known as PSF1) belongs along with *GINS2* (also known as PSF2), *GINS3* (also known as PSF3), and *GINS4* (also known as SLD5) to the heterotetrameric Go-Ichi-Ni-San (GINS) complex, which, together with the MCM complex, is required for DNA replication (12, 13). To ensure that the entire set of genetic information is replicated once, and only once, per division, DNA replication is tightly regulated and coordinated with the cell cycle (14–16). The first step is the recruitment of CDT1, CDC6, and an inactive form of the MCM complex to the origin recognition complex (ORC) at origins of replication, to yield the pre-replicative complex (pre-RC) during the G<sub>1</sub> phase (17). The second step is the recruitment of CDC45 and the GINS complex, to form the CDC45-MCM-GINS (CMG) complex, during the transition of G<sub>1</sub>/S phase, to trigger the firing and the elongation of replication forks in S-phase (12, 13, 18, 19). Sanger sequencing of *GINS1* in patients and their parents showed that P1 and P2 were compound heterozygous for the two following variants: a 5' UTR variation (c.-48C>G) predicted to create a new donor splice site (NetGene2 [http://www.cbs.dtu.dk/services/NetGene2/] score 0.85; Combined Annotation Dependent Depletion [CADD, http://cadd.gs.washington.edu/] score 3.6, for a *GINS1*-specific mutation significance cutoff [MSC, http://lab.rockefeller.edu/casanova/MSC] score of 16.5) and a missense variation (c.247C>T) in exon 4, resulting in the replacement of an arginine with a cysteine residue in position 83 (p.R83C), a change predicted to be damaging (CADD score 35 for a *GINS1*-specific MSC of 16.5) (20, 21) (Figure 2A and Supplemental Figure 4, A and B).

*Compound heterozygous GINS1/PSF1 mutations in kindreds B, C, and D.* Subsequently, we identified compound heterozygous *GINS1* rare mutations by WES in 3 other, unrelated patients from kindreds B, C, and D. Their parents were all heterozygous for one of each of the 4 mutations. P3 has a substitution in the 5' UTR, at position c.-60A>G (Figure 2A and Supplemental Figure 4, A and B), which is predicted to create a new donor splice site (NetGen2 score 0.87, CADD score 10.4). P3 and P5 both have the missense substitution of P1 and P2 (c.247C>T, p.R83C) in exon 4 (Figure 2A and Supplemental Figure 4, A and B), while P4 and P5 both have the 5' UTR mutation of P1 and P2 (c.-48C>G). Finally, P4 also has

a c.455G>A substitution in exon 6 leading to the replacement of a cysteine with a tyrosine residue in position 152 (p.C152Y), which is predicted to be damaging (CADD score 32) (Figure 2A and Supplemental Figure 4, A and B). Overall, the 5 patients from 4 unrelated kindreds studied were found to be compound heterozygous for only 4 rare variants, including two missense (p.R83C and p.C152Y) and two 5' UTR nucleotide substitutions (at positions -48 and -60 relative to the ATG). Only the R83C substitution was found in 1000 Genomes, with a low MAF (4 per 10,000). Both the R83C and C152Y substitutions were reported in the Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.org/), with low MAFs of 9 and 0.25 per 10,000, respectively. The 5' UTR variants were not reported in any databases, nor were they detected in 945 healthy controls from 52 ethnic groups from the Centre d'Etudes du Polymorphisme Humain–Human Genome Diversity (CEPH-HGD) panel. There are currently no double-heterozygous non-synonymous mutations, and there is only one homozygous mutation (E35G) found in our in-house and public databases with a MAF of 3.8 and 1.4 per 1,000 in 1000 Genomes and ExAC, respectively (Supplemental Figure 4B and Supplemental Tables 5 and 6). The gene damage index (GDI) of 2.48 for *GINS1* is intermediate, and its neutrality index estimate of 76.2 shows that it is under strong positive selection (22, 23). These data suggest that the 4 variants identified are more likely to be rare pathogenic mutations than irrelevant polymorphisms. Haplotype analysis at the *GINS1* locus suggested that the 2 recurrent alleles (R83C and c.-48C>G) were not due to founder effects and that the patients did not share a common ancestor (data not shown). In the 4 kindreds, familial segregation patterns of the *GINS1* genotype and clinical phenotype were consistent with AR inheritance with complete penetrance (Figure 2A).


*The 5' UTR mutations in GINS1 affect mRNA splicing and are leaky.* We assessed the impact of the 5' UTR variants by studying *GINS1* mRNAs in cell lines derived from all patients. HPVE6/E7-transformed fibroblast cell lines (E6/E7-fibroblasts) contained normal or reduced levels of *GINS1* mRNA, as assessed by quantitative real-time RT-PCR (qPCR) (Supplemental Figure 4C). Thus, the mutations might affect the production of *GINS1* mRNA. As the 5' UTR mutations were predicted to create new donor splice sites, we searched for alternative splicing products. Amplification of the



**Figure 4. Abnormal nuclear structure and cell cycle defects in primary cells of patients with *GINS1* mutations.** (A) Nuclear abnormalities visualized and quantified in 100 cells analyzed by fluorescence microscopy after DAPI staining on primary fibroblasts. Left: Images illustrating the different nucleus morphologies observed in patients' cells. Right: Cells were scored as normal or having cytokinesis abnormalities (1), micronuclei (2), multi-lobed nuclei (3), and nuclei with grossly abnormal morphology (4) ( $n = 3$ ; 3 independent controls in each experiment). (B) Left: Image illustrating the increased nucleus size in P3 versus a control. Right: Measurement of nucleus area with ImageJ software after DAPI staining of primary fibroblasts (\*\* $P < 0.001$ ; 1-way bidirectional ANOVA). (C) Cell cycle analysis by BrdU/propidium iodide staining of unsynchronized primary fibroblasts from healthy control (CTL) and 3 patients (P2, P3, and P4). Results are representative of 3 independent experiments. (D) Growth curve (left) and viability (right) of primary fibroblasts from 5 healthy controls and 3 patients (P2, P3, and P5). Results are representative of 2 independent experiments.

5' UTR of the *GINS1* cDNA from all patients, heterozygous individuals and control EBV-B cell lines or E6/E7-fibroblasts yielded a product of the expected MW for all individuals and a product with a lower MW only for individuals carrying a 5' UTR mutation (Figure 2B). Sequencing of this product confirmed that it was a truncated form of *GINS1* cDNA, with two forms corresponding to a deletion of 123 or 135 nucleotides from the c.-48C>G or c.-60A>G variant to the beginning of exon 2, respectively (Supplemental Figure 4D). The canonical translation initiation codon is located in exon 1, so these mutations are predicted to be deleterious. We further characterized the impact of the two 5' UTR variants on mRNA splicing by analyzing the full-length *GINS1* cDNAs obtained from the E6/E7-fibroblasts of patients and controls by PCR. We quan-

tified the various cDNA species by cloning and sequencing 100 individual *GINS1* cDNA molecules from P2, P3, P4, and P5 E6/E7-fibroblasts. About 30% of *GINS1* clones carried one of the missense mutations, suggesting that these mRNAs are stable. We found that 7%, 3%, 10%, and 8% of full-length cDNAs, respectively, carried the 5' UTR mutation in P2, P3, P4, and P5 (Figure 2C), suggesting that splicing using the new donor splice site created by the mutations was not fully efficient. The principal splicing event was the deletion of 123 or 135 bp, as described above, but other types of aberrant splicing were also observed (data not shown). These results suggest that the two 5' UTR variants do not abolish the production of the full-length transcript, allowing about 5%-10% residual expression of the full-length mRNA correspond-




**Figure 5. GINS1 mutations are associated with poor ATR pathway activation. (A)** Cell cycle analysis by BrdU/propidium iodide staining on E6/E7-fibroblasts from a healthy control (CTL) and 2 patients (P2 and P4) from the indicated time points (0, 4, 12, to 20 hours) after nocodazole synchronization. Results are representative of 3 independent experiments. **(B)** Percentage of E6/E7-fibroblasts from controls and patients positive for senescence-associated  $\beta$ -gal activity ( $n = 3$ , 300 cells analyzed/experiment), as determined by microscopy. (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ; 1-way bidirectional ANOVA). Original magnification,  $\times 20$ . **(C)** Phosphorylation of CHK1 and RPA, assessed by Western blot analysis of total protein extracts from untreated or treated (incubation for 20 hours with 0.5 or 2 mM HU) E6/E7-fibroblasts from controls and patients, with antibodies against P-CHK1, P-RPA, CHK1, and RPA. GAPDH was used as a loading control. The data shown are representative of 3 independent experiments.

ing to the WT coding region in heterozygous cells, relative to the levels in control cells. Thus, although deleterious, these variants are therefore hypomorphic, potentially accounting for the live birth of the patients, while targeted deletion of *Gins1* causes early embryonic lethality in mice (24).

**GINS1 protein production from the mutant alleles.** We investigated the proteins encoded by the mutant *GINS1* alleles by transfecting HEK293T cells with various expression vectors carrying C-terminally Flag-tagged WT or mutant *GINS1* cDNAs, such as the R83C and C152Y variants, and the most common abnormal product of the two 5' UTR mutations (deletion of exon 1, designated as  $\Delta E1$ ). As expected, WT, R83C, and C152Y variant cDNA encoded a single full-length 26-kDa protein (Figure 3A). By contrast, cells transfected with  $\Delta E1$  generated lower-MW products, suggesting that translation was initiated from a downstream ATG. There are 3 putative ATG codons in the  $\Delta E1$  construct, in positions 36, 106, and 111, giving rise to proteins of approximately 22, 16, and 14

kDa, respectively. We investigated the possibility that these lower-MW proteins result from downstream initiation by transfecting HEK293T cells with various Flag-tagged expression vectors of WT and various  $\Delta E1$  *GINS1* cDNAs carrying different methionine-to-glycine substitutions: M36G ( $\Delta E1$ -ATG1), M106G ( $\Delta E1$ -ATG2), M111G ( $\Delta E1$ -ATG3), or all 3 mutations ( $\Delta E1$ -ATG1-3) (Figure 3B). Western blots with anti-Flag and anti-GINS1 antibodies revealed 3 proteins of ~22, ~16, and ~14 kDa in  $\Delta E1$ -transfected cells, not detectable with an antibody raised against the N-terminus of GINS1 (data not shown), with one of these proteins in each case selectively absent from cells transfected with  $\Delta E1$ -ATG1,  $\Delta E1$ -ATG2, or  $\Delta E1$ -ATG3. None of these proteins were detected in  $\Delta E1$ -ATG1-3-transfected cells (Figure 3B). Thus, the alternatively spliced mRNAs are competent for the translation re-initiation from 3 different ATG codons downstream from the original ATG codon.

**Impaired expression of GINS1 protein and some GINS complex components.** GINS1 forms a highly conserved heterotetramer



**Figure 6. GINS1 mutations are associated with increased DNA damage.** Top: E6/E7-fibroblasts were seeded on glass coverslips before treatment with 0.5 or 2 mM HU for 20 hours or left untreated. Cells were fixed before staining with  $\gamma$ H2AX and 53BP1 antibodies and DAPI. Bottom: Quantification of slides for percentage of cells with at least 3 foci. Values represent the mean averages  $\pm$  SEM of scoring from 3 independent experiments (\* $P$  < 0.05, \*\* $P$  < 0.01, \*\*\* $P$  < 0.001; 1-way bidirectional ANOVA).

complex with GINS2, GINS3, and GINS4, known as the GINS complex (18, 19). Overexpression experiments in NIH3T3 cells showed that GINS1 expression levels might affect the levels of the other GINS complex components (25). For this reason, all GINS proteins levels in E6/E7-fibroblasts from controls and patients were assessed. Cells from patients had lower GINS1 protein levels than control cells (40% of WT on average, ranging from 29% to 53%), suggesting that both 5' UTR and missense mutations affected protein levels (Figure 3C and Supplemental Table 7). Interestingly, GINS3 and GINS4 levels were also lower in the E6/E7-fibroblasts of patients (17% of WT on average, ranging from 10% to 27%, and 65%, ranging from 44% to 88%, respectively), whereas GINS2 and MCM4 levels were normal (Figure 3D and Supplemental Table 7). Lentiviral transduction of P2 E6/E7-fibroblasts with WT GINS1, but not the empty vector, R83C, or  $\Delta$ E1-GINS1 allele, restored GINS1 and GINS3 expression, as assessed by Western blotting (Figure 3E). Thus, GINS1 contributes to the stability of other components

of the GINS complex, but probably not of the MCM complex. The complementation of the expression levels of other components of the GINS complex also confirms that the GINS1 mutations are deleterious.

*Impaired function of the N-terminal-truncated and missense GINS1 proteins.* We assessed the functional consequences of each GINS1 mutation by studying the formation of the GINS complex in transfection experiments. The mutant proteins were produced in HeLa cells, in which the R83C and  $\Delta$ E1 proteins failed to form the 4-subunit GINS complex (Figure 3F), unlike the WT and C152Y proteins. These results are consistent with the crystal structure of human GINS1 (18). Indeed, the N-terminus (or alpha helix-rich [A] domain; residues 1-145) of GINS1 has been implicated in interactions with GINS3 and GINS4, whereas the C-terminus (or beta strand-rich [B] domain; residues 146-196) is dispensable for GINS complex formation (18, 26). However, Chang et al. suggested that the B-domain may be important for interactions with GINS complex partners, such as MCMs, CDC45, or DNA polymerases (18), and Sengupta et al. have shown that in yeast, the C-terminus of GINS1 interacts with DPB2, a subunit of DNA polymerase  $\epsilon$  (27). The C152 amino acid is located in the B-domain; we therefore investigated CMG complex formation and its binding to DNA. In a baculoviral expression system using Sf9 insect cells, CMG complex formation with the C152Y protein was only 17% of that observed with the WT protein (Figure 3G), despite the production of similar amounts of the WT and C152Y proteins (Supplemental Figure 5A) and the assembly of GINS complexes (Figure 3F). We investigated the consequences of the C152Y mutation for the CMG complex further by measuring the ATPase and helicase (Supplemental Figure 5, B and C) activities of the mutant complex in vitro. No differences in the specific activity of the CMG-WT and CMG-C152Y mutant complexes were observed, suggesting that the C152Y mutation affects the formation of the CMG complex but not its activity once it has been formed. These results show that the R83C and C152Y alleles are loss-of-function and hypomorphic, respectively, in terms of their functional impact on GINS and CMG complex formation. The two 5' UTR mutations are hypomorphic due to residual correct splicing leading to production of a small amount of WT mRNA, with the N-truncated products being loss-of-function. Our findings indicate that the 5 patients are compound heterozygous for 2 deleterious GINS1 alleles, at least one of which is hypomorphic (C152Y, c.-48C>G, c.-60A>G) and no more than one of which is loss-of-function (R83C).

*Nuclear and cell cycle abnormalities in primary GINS1-deficient fibroblasts.* The maintenance of genomic integrity requires complete and accurate DNA replication (14-16). A previous study showed that the in vitro depletion of GINS2 in asynchronous HeLa cells promotes an aberrant nuclear morphology and chromosome mis-segregation defects (28). We investigated these phenotypes in the patients' cells, with DAPI staining on dermal primary fibroblasts at an early passage. Abnormal nuclear morphology was observed in GINS1-deficient cells, including micronuclei, as well as misshapen and multilobed nuclei (Fig-

**Table 1. Correlation between clinical phenotype and genotype**

Genotype	c.-48C>G/R83C	c.-60A>G/R83C	c.-48C>G/C152Y
Kindred	A, D	B	C
Patient	P2, P5	P3	P4
Proportion of altered transcripts (altered splice/missense)	58/35	73/24	55/35
Proportion of WT transcript	7-8	3	10
Activity of each allele (altered splice/missense)	0/0	0/0	0/17
Estimated residual CMG activity	7%-8%	3%	15%-16%
Replication speed	Increased	Increased	Normal
Checkpoint activity	Impaired	Impaired	Impaired
DNA damage markers	High	High	Intermediate
Immune phenotyping	Low NK cells and neutrophils	Low T, B, NK cells and neutrophils	Low NK cells and neutrophils
Clinical severity	++	+++	+


ure 4A). Moreover, cell population analysis showed that GINS1-deficient cells had a significantly larger mean nuclear size (Figure 4B), suggesting an impaired cell cycle. This result is consistent with the finding that the depletion of GINS1 and GINS2 is associated with an impaired S-phase progression in human dermal fibroblasts (28). We further analyzed the cell cycle in unsynchronized primary fibroblasts from 3 of 4 patients. There were decreased percentages of cells in G<sub>1</sub> phase and increased percentages of G<sub>2</sub>/M cells in patients, as compared with controls, with the most pronounced phenotype in P3 cells (Figure 4C), which also had the largest mean nuclear size. In addition, higher proportions of cells with abnormal DNA content were observed in P2 and P3, but not P4 (Figure 4C). Finally, primary fibroblasts from GINS1-deficient patients proliferated more slowly but displayed a similar death rate, as estimated by trypan blue staining, compared with their WT counterparts (Figure 4D). Altogether, these morphological changes and cell growth characteristics are suggestive of senescent cells (29), due to an impaired DNA replication.

**DNA damage and checkpoint signaling in patient cells.** To further study the proliferation defect, we analyzed the progression of the normal cell cycle in E6/E7-fibroblasts after release from nocodazole, which synchronizes cells in M phase. At 4 hours after release by mitotic shake-off, a lower proportion of patients' cells were in G<sub>1</sub> phase, as compared with controls. In addition, at 12 hours after release, only 2%-3% of patients' cells were in S phase, compared with 8%-10% of the controls, and 20 hours after release, the proportion of cells in S phase was similar in controls and P4, which has the greatest GINS1 expression level, but was still low in P2 (Figure 5A). We also investigated whether a senescence-like state may occur prematurely in E6/E7-fibroblasts from patients by carrying out  $\beta$ -galactosidase ( $\beta$ -gal) staining in the absence or presence of H<sub>2</sub>O<sub>2</sub> (120  $\mu$ M). The analysis showed that  $\beta$ -gal staining in untreated cells was higher in fibroblasts from patients than from controls (Figure 5B), indicative of increased senescence. The phenotype in G<sub>2</sub>/M to G<sub>1</sub> transition is consistent with increased DNA damage that needs to be resolved during mitosis to allow for cell cycle transition (30). Previous studies have shown that depletion of GINS1 and GINS2 by specific siRNAs in human dermal fibroblasts induces replication stress (28). To assess the response

of GINS1-deficient E6/E7-fibroblasts to replication stress, we evaluated CHK1 and RPA phosphorylation after treatment with hydroxyurea (HU). Although HU treatment led to robust induction of CHK1 and RPA phosphorylation in control cells, that response was much more muted in GINS1-deficient cell lines (36% and 45% [P-CHK1], 48% and 75% [P-RPA] on average of controls) (Figure 5C and Supplemental Table 8). Replicative stress may also lead to genomic instability. We evaluated the presence/accumulation of DNA damage markers, such as the phosphorylation of  $\gamma$ H2AX and 53BP1, with or without HU treatment, by immunofluorescence. We observed higher numbers of spontaneous  $\gamma$ H2AX and 53BP1 foci in the P2, P3, and P5 E6/E7-fibroblasts than in control fibroblasts (Figure 6), suggesting an increase in basal replication stress and DNA damage when GINS1 is deficient.

P4 cells, with higher levels of functional GINS1, displayed an intermediate phenotype in this assay. HU treatment increased markers of damage in both control and patient cells (Figure 6), suggesting that the ataxia telangiectasia mutated (ATM) pathway may be compensating in patients' cells. To test ATM activity, we assessed the phosphorylation of CHK2 by Western blot analysis following treatment with phleomycin, which creates dsDNA breaks. We observed normal induction of CHK2 phosphorylation in patients' E6/E7-fibroblasts, as compared with controls (Supplemental Figure 6). These results indicate that ataxia telangiectasia and Rad3-related protein-dependent (ATR-dependent), but not ATM-dependent, signaling is defective when cells do not have a full complement of CMG complexes. Levels of GINS/CMG complexes below 10% of those in controls were associated with a basal induction of replication stress and impaired ATR/CHK1 pathway activation upon HU treatment, while only an impairment of ATR/CHK1 pathway induction, but no basal replication stress, was observed when complex levels were between 15% and 20% of control levels (Table 1).

**Abnormal replication pattern in cells deficient in GINS1.** GINS complex recruitment is essential for replication origin firing (13, 31). To directly investigate replication patterns in cells deficient for GINS1, we carried out DNA fiber combing analysis (Figure 7A) (32, 33). Assessment of 300 independent DNA fibers per cell line revealed greatly decreased numbers of replication clusters and fewer bidirectional replication forks in cells from patients, when compared with those from controls (Figure 7A). This most likely reflects a smaller number of firing replication forks in the patients' cells. Interestingly, analysis of 50 initiation bidirectional forks showed higher replication rates in E6/E7-fibroblasts of all patients except P4 (Figure 7B), suggesting that the replication speed is increased to compensate for the decreased number of active replication forks. Such a compensatory effect has already been reported in vitro, when the dNTP levels were increased or decreased by chemical treatments (34, 35). Importantly, expression of the WT GINS1 allele significantly decreased the replication speed, bringing it into WT range, whereas expression of the mutant R83C or  $\Delta$ E1 alleles did not (Figure 7C). Furthermore, assessment of 50 independent initiating bidirectional forks showed an increase in stalled forks



**Figure 7. GINS1-deficient patient cells show impaired DNA replication.** (A) Left: Scheme of the protocol used for double-pulse labeling of replication forks in asynchronous E6/E7-fibroblasts. Successive pulses with CldU and IdU enable recognition of ongoing forks, and initiation and termination events. Red and green arrows represent neo-synthesized DNA labeled with CldU (first pulse) and IdU (second pulse), respectively. Representative pictures of DNA fibers of replication, initiation, termination, uni- or bidirectional forks and clusters are shown. Right: Analysis of replication parameters in untreated E6/E7-fibroblasts from patients and 3 independent controls (CTL). Quantification of all events in 300 fibers was analyzed in 2 independent experiments. One representative control is shown. (B) Measurement of the CldU signal length of 50 CldU+IdU bidirectional starting signals. Measurement was done in patients and 3 independent controls in 2 independent experiments; red bars represent the mean. One representative control is shown. (C) Measurement of the CldU signal length of 50 CldU+IdU bidirectional starting signals from control and P2 E6/E7-fibroblasts lentiviral transduced by empty vector (EV); or GINS1-WT (WT), GINS1-R83C (R83C), or GINS1- $\Delta\text{E1}$  ( $\Delta\text{E1}$ ); or not transduced (NT). The experiment was repeated two times. Red bars represent the mean. (D) Quantification of normal/stalled/collapsed replication forks in 50 bidirectional starting signals from patients and 3 independent controls. Replication forks were considered to have collapsed if there was no IdU signal or this signal was  $\leq 10\%$  of the CldU signal.  $***P < 0.001$ ; 1-way bidirectional ANOVA. Quantification was analyzed in 2 independent experiments. One representative control is shown.

(length of IdU tract  $\leq 10\%$  of length of CldU tract) in patients' cells (Figure 7D). Overall, these results suggest that the WT GINS1 protein levels produced by the patients' cells is sufficient to initiate DNA replication but not to activate all replication origins, with a potential impact on the regulation and stability of replication forks. Altogether, our results provide evidence for a quantitative threshold of functional GINS/CMG complexes, responsible for the tight genotype-phenotype correlation observed in patients (Table 1).

## Discussion

We describe here patients with inherited, partial GINS1 deficiency. Compound heterozygous *GINS1* mutant alleles were found to underlie an AR disorder in 5 patients from 4 non-consanguineous and unrelated European families from France ( $n = 3$ ) and Britain ( $n = 1$ ). All displayed intrauterine growth retardation, chronic neutropenia, and NK cell deficiency. Four also had postnatal growth retardation, severe infections (mostly viral), and cancer. The clin-

ical phenotype of these patients is milder than that of inbred mice homozygous for a null allele of *Gins1*, which die in utero at the implantation stage (24). The presence of at least one hypomorphic allele in each patient most likely explains their survival and development, although with growth retardation. Consistent with this hypothesis, the only patient with two hypomorphic alleles (P4) had the mildest growth retardation ( $-2.5$  SD at birth and no postnatal growth retardation), whereas patients with one hypomorphic and one loss-of-function allele (P2, P3, P5) had more severe growth retardation ( $-4/-6$  SD, both pre- and postnatal) (Table 1). Overall, the global pre- and postnatal development phenotype of the patients was consistent with the ubiquitous expression of and requirement for the GINS1-containing GINS complex for DNA replication and cell proliferation (19).

The overall impact of GINS1 deficiency on pre- and postnatal development is reflected in experiments testing various relevant phenotypes in dermal fibroblasts. The residual GINS1 activity, estimated with the percentage of WT expressed allele and the CMG formation, in the patients' cells was sufficient to initiate DNA replication. However, the low level of CMG complexes available is associated with a reduced number of active replication forks in the patients' cells. In Chinese hamster fibroblasts, it was reported that an increased replication speed will impact the density of initiation events, with a lower number of active forks (35). Interestingly, we observed a higher replication speed in cells from patients, suggesting that the increased speed may compensate for the low number of active forks. In addition, we observed abnormally low phosphorylation of the CHK1 and RPA proteins in the patients' cells upon HU treatment. This result is similar to those reported in yeast, where the intensity of intra-S-phase checkpoint activation correlates with the number of active forks (36), suggesting that the level of checkpoint responses, normally coordinated by ATM and ATR in response to the genotoxic effect of replication stress (37), may be regulated by a threshold of active replication forks in human cells. As CMG activity is necessary for single-stranded DNA (ssDNA) production, itself required for the activation of the ATR pathway (38, 39), fewer active forks would produce impaired activation of the DNA damage response. In turn, the compromised signaling would result in DNA damage and genome instability, as observed by increase in  $\gamma$ H2AX and 53BP1 staining in dermal fibroblasts and accompanying cellular growth arrest. Overall our data are consistent with GINS1 being involved not only in the initiation of DNA replication but also in ATR-mediated checkpoint control during S-phase progression.

Mutations of *GINS1* and *MCM4* both result in fibroblast phenotypes that reflect and perhaps underlie pre- and postnatal growth retardation, but affected patients also display gene-specific clinical manifestations. Adrenal insufficiency has been reported in patients with *MCM4* deficiency (5, 6) but was not observed in any of the patients with *GINS1* deficiency. Conversely, patients with *MCM4* deficiency do not display chronic neutropenia (5, 6). These observations suggest that the GINS and MCM complexes may play specific, non-redundant roles that may not be based on their interaction. Alternatively, the levels of residual *MCM4*- and *GINS1*-dependent DNA replication activity may differ between patients with *MCM4* and *GINS1* mutations, accounting for these differences. Neutrophil precursors in the bone marrow normally go through

a phase of proliferation (myeloblasts to metamyelocytes), followed by a phase of differentiation (metamyelocytes to neutrophils), before migrating to the blood. The low proportion of metamyelocytes and neutrophils in the bone marrow of patients with *GINS1* mutations is consistent with an impact of GINS1 deficiency on the cell cycle and maintenance of neutrophil progenitors. GINS1 deficiency is thus a new genetic etiology of congenital chronic neutropenia (40). The other myeloid lineages appear to develop normally. However, surprisingly, the patients rarely displayed the typical acute or chronic infections observed in neutropenic children and adults, even in the absence of prophylaxis, suggesting that the bone marrow blockade might be overcome upon infectious challenge. Accordingly, normal neutrophil counts were measured upon G-CSF treatment and in the course of natural infections.

Besides these gene-specific differences, the salient feature common to patients with *MCM4* and *GINS1* mutations leading to their study was not their growth retardation, but a profound NKD (5, 6, 8, 9). Unlike the neutropenia, the patients' NK cell deficit was permanent. Both *MCM4* and *GINS1* deficiencies selectively affect the NK cell branch of the lymphoid lineage, with no major detectable effect on the development of T and B lymphocytes (8). *GINS1* deficiency affects the CD56<sup>dim</sup> subset of NK cells, like *MCM4* deficiency, but also the CD56<sup>bright</sup> subset (albeit to a lesser extent), unlike *MCM4* deficiency. This suggests that the defect of NK cell development in patients with *GINS1* mutations occurs upstream from or is more profound than that of patients with *MCM4* mutations. As in cells from patients with *MCM4* mutations (5), but not in those from healthy controls, the few blood NK cells in *GINS1*-deficient patients displayed impaired responses to IL-2 and IL-15, as previously reported for the T lymphocytes of P2 (9). Overall, the MCM and GINS complexes play crucial and related roles in the maintenance of NK cells. By analogy with our previous results (5, 9), we hypothesized that the NK cell deficit is due to a defect of cell survival. Residual *MCM4* or *GINS1* activity is sufficient for the normal development of most lymphoid subsets, but not for that of MAIT cells, NKT cells and some ILCs, including NK cells in particular. The NK cell deficit is the most pronounced lymphoid deficit in both *MCM4* and *GINS1* deficiencies. The patients developed lymph nodes, suggesting that lymphoid tissue inducer (LTI) cell development is unaffected, contrary to what was observed for ILC2 and ILC3 cells. Our data suggest that a proliferation step is crucial for some ILC subsets, and that this step occurs downstream from the common ILC precursor (CILP) cells, also referred to as CXCR6<sup>+</sup>IL-7R $\alpha$ <sup>+</sup>  $\alpha$ -LP (lymphoid progenitor) cells, which may give rise to NK cells and other ILC subsets (41).

The mechanisms responsible for this selective impact of *MCM4* and *GINS1* deficiencies in NK cell development remain to be identified. There might be a defect in the signaling pathways controlling cell proliferation and/or survival signaling. Several hypotheses appear worth testing experimentally. First, the nature of the signals necessary for the development of B, T, and ILC lineages is different. The differentiation of adaptive lymphocytes is controlled by pre-B cell receptor (pre-BCR) for B lymphocytes and by pre-T cell receptor (pre-TCR) and  $\gamma$ c-related cytokine signaling for T lymphocytes, whereas ILC, or at least NK cell, development seems to be strictly cytokine dependent (42). Thus, the selective impact of GINS and *MCM4* on ILCs, when compared with con-

ventional B and T cells, might result from signals initiated by pre-BCR and pre-TCR, which could modify cell proliferation, apoptosis/senescence, or both, whereas cytokine signaling alone might not (43, 44). Second, whereas the control of DNA breaks is a critical part of the development of T and B cells, NK cells and other ILCs do not productively rearrange the gene segments encoding for antigen receptors. It is therefore possible that the molecular machinery controlling DNA integrity and DNA repair is regulated differently in adaptive lymphocytes versus ILCs. Although the impact of GINS1 deficiency on MAIT and NKT cells does not fully support this possibility, it remains that MAIT and NKT cells express invariant T cell receptors and might experience fewer DNA breaks during development. It would thus be interesting to evaluate whether members of the CMG complex participate in other DNA transactions beyond DNA replication. Along this line, it has been recently reported that the RAG recombinase may play a novel function beyond V(D)J recombination, and endow ILCs including NK cells with a better response to DNA damage and repair of DNA breaks (45). Finally, the NK phenotype of patients with MCM4 or GINS1 deficiency might be related to POLE1 and POLE2 deficiency, two inborn errors of DNA replication that underlie a complex phenotype including NKD and growth retardation (46, 47). Irrespective of these data, our results suggest that the maintenance of human NK cells and some ILCs, as well as that of neutrophils, is more dependent of the integrity of the MCM-GINS multi-molecular complex than other lymphoid and myeloid lineages, attesting to the strong dependence of the process on replication and genomic stability during their development.

## Methods

*Case reports.* Detailed clinical features of the patients are described in Supplemental Table 1.

Briefly, two children from kindred A had very few or no NK cells and neutrophils in their peripheral blood. Both were born with severe intra- and extrauterine growth retardation, microcephaly, and mild dysmorphism. At the age of 5 months, the index case, P1, born in 1993, was diagnosed with atopic dermatitis, followed by generalized erythroderma desquamativa. A new episode of erythroderma was diagnosed at the age of 9 months. High serum IgE levels and high eosinophil counts were reported. At the ages of 1 year and 18 months, she developed episodes of pneumonia, with no pathogen isolation in the first episode and CMV infection diagnosed in the second. The patient suffered hemodynamic failure and died. This patient had previously experienced recurrent childhood viral infections, with recurrent respiratory tract infections and lung disease consisting of bronchiectasis, fibrosis, and respiratory failure. Her younger sister P2 was born in 1998. The karyotype analysis done in blood at 3 months of age was normal. Serum IgE and eosinophil counts were normal. No autoantibodies were detected. At 17 months of age, she developed eczematous lesions. She has had no unusual infections, but is on prophylactic antibiotic treatment due to neutropenia. She displayed growth retardation associated with insufficient growth hormone secretion and was treated with synthetic growth hormone between the ages of 4 and 12 years. However, this treatment was stopped when she developed an osteosarcoma at the age of 12 years. She received two lines of chemotherapy, the first based on methotrexate and adriamycin for 3 months followed by local conservative surgery and the second based on VP16,

iphosphamide, cisplatin, and adriamycin for 4 months. She recovered well after these treatments and has been healthy ever since, except for one respiratory infection, probably due to a bacterium.

In kindred B, patient P3, born in 2008, presented with a complex syndrome including severe intra- and extrauterine growth retardation, mild facial dysmorphism, some facial features of premature aging, and immunodeficiency, with a particularly low NK cell count in peripheral blood. The karyotype analysis done at 3 months of age was normal. Serum IgE and eosinophil counts were normal. No autoantibodies were detected. Reduced myelopoiesis and erythroid dysplasia were documented in bone marrow analysis. The growth retardation was extremely pronounced and did not respond to enteral feeding support including percutaneous endoscopic gastrostomy (PEG) feeding or to parenteral feeding. P3 presented multiple episodes of severe viral infections, including prolonged acute CMV and varicella zoster (VZV) infection, several severe airway infections with adenovirus and respiratory syncytial virus (RSV) requiring hospitalization, and multiple episodes of diarrhea and gastroenteritis. Only during two of the many diarrheal episodes was a viral infection detected (astrovirus and rotavirus). The diarrhea was associated with severe protein-losing enteropathy. Progressive lymphopenia and neutropenia were observed, particularly during periods of infection. Due to low serum IgM and IgG levels, particularly during episodes of protein-losing enteropathy, immunoglobulin replacement and antibiotic prophylaxis were initiated, greatly decreasing the frequency of airway infections.

In kindred C, patient P4, born in 1986, displayed intrauterine growth retardation (though extrauterine growth was normal), and had low NK cell and neutrophil counts. The karyotype analysis done in blood at 9 years of age was normal. She developed dry skin and ichthyosis phenotypes. Eosinophil counts were normal. No autoantibodies were reported. A slight dysgranulopoiesis was documented in bone marrow analysis. She received prophylactic antibiotic treatment (trimethoprim/sulfamethoxazole) from 15 to 24 years of age. In the first few months of life, she developed post-vaccination abscesses and vulvar boils. At the age of 1 year, she developed a severe necrotizing varicella infection, associated with lymphadenopathy. At the ages of 2 and 7 years, she had herpes simplex infections with lymphadenopathy. At the age of 9 years, she developed folliculitis with associated lymphadenopathy and had widespread boils over a period of 10 months. A staphylococcal infection was suspected. The patient experienced repeated ear, nose, and throat (ENT) and digestive infections (of unknown etiology) during her teenage years. She developed several fungal lesions of the scalp at the age of 14 years and had another staphylococcal infection at the age of 17 years. She was tested several times for viruses, and positive serological test results were obtained for CMV, EBV, and VZV, although no viruses were detected in her blood. She experienced an ENT infection associated with a lymphadenopathy at the age of 20 years and since has been healthy.

In kindred D, patient P5, born in 1997, displayed severe intra- and extrauterine growth retardation, despite enteral and parenteral support and growth hormone therapy. No increases in sister chromatid exchanges and in DNA breaks were found in karyotype analysis done in bone marrow, blood, and fibroblasts. However, an increase in endomitosis was noticed in blood and fibroblast cells at 10 years of age. Myelodysplasia was documented in bone marrow analysis. She experienced precocious chronic diarrhea linked to bacterial episodes, food allergies, and villous atrophy. Her cutaneous phenotype includ-

ed initial atopic dermatitis, lipoatrophy, and pale and thin skin. Serum IgE and eosinophil counts were normal. At the age of 5 years, she developed severe glaucoma that steadily worsened and progressed to definitive bilateral blindness. She had recurrent viral or bacterial pulmonary infections: mild neutropenia with dysmyelopoiesis was noticed from the age of 1 year, hypogammaglobulinemia and low NK cell counts from the age of 7 years, and progressive lymphopenia. At the age of 13 years, she developed *Aspergillus nidulans* pneumonia. Prophylactic cotrimoxazole was initiated at 3 years of age, immunoglobulin replacement at age 7 years, and daily caspofungin and G-CSF therapy at age 13 years; all of these have continued to the present. From the age of 9, she had 4 severe episodes of autoimmune hemolytic anemia (a Coombs test was positive), treated with short steroid courses, rituximab, cyclosporine, and azathioprine and complicated by a severe hemophagocytic syndrome at the age of 10 years.

**Whole-exome sequencing.** Whole-exome sequencing was carried out, as previously described, with the Agilent SureSelect Human All Exon 50 or 71 Mb Kit (Agilent Technologies) for exome capture. Paired-end sequencing generated 100 base reads, sequences were aligned with the hg19 build of the human genome, and all calls with a read coverage of less than 2× and a phred-scaled SNP quality of less than 20 were filtered out.

**Cell purification and culture.** Fresh human PBMCs were isolated by Ficoll-Hypaque centrifugation (Amersham Pharmacia Biotech) from whole-blood samples. Lymphoblastoid cell lines (EBV-B) were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gibco BRL; Invitrogen). Primary and transformed E6/E7-fibroblasts were maintained in DMEM medium supplemented with 10% heat-inactivated FCS (Gibco BRL; Invitrogen).

**DNA, RNA, PCR, sequencing.** Genomic DNA and RNA were purified from blood, EBV-B cells, or E6/E7-fibroblasts. Total RNA was extracted with TRIzol (Invitrogen) and reverse transcribed with SuperScript II Reverse Transcriptase (Invitrogen). The *GINS1* cDNA was amplified with different pairs of primers. PCR was performed with *Taq* polymerase (Invitrogen). The products were sequenced with the BigDye Terminator cycle sequencing kit and analyzed on a 3130 ABI Prism Genetic Analyzer (Applied Biosystems).

**Determination of mRNA levels by qPCR.** Total RNA was purified with the RNeasy plus Micro Kit (QIAGEN) and reverse transcribed with the High Capacity RNA-to-cDNA kit (Applied Biosystems). qPCR was performed in an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) using an exon-spanning probe for *GINS1* (Hs01040835\_m1, Applied Biosystems), with normalization to the  $\beta$ -glucuronidase (*GUS*) housekeeping gene by the  $\Delta$ Ct method.

**Western blots.** Cells were lysed in 1% Triton X-100 lysis buffer plus protease and phosphatase inhibitors. Samples were subjected to criterion TGX precast 10% or 18% gel separation and transferred onto membranes by iBlot Gel Transfer (Invitrogen). Primary anti-Flag (OriGene, 4C5), anti-*GINS1* (10R-1766, Fitzgerald), anti-*GINS2* (A304-140A, Bethyl Laboratories Inc.), anti-*GINS3* (15651-1-AP, ProteinTech), anti-*GINS4* (ab139683, Abcam), anti-CHK1 (2G1D5, Cell Signaling Technology), anti-phospho-CHK1 (S317) (D12H3, Cell Signaling Technology), anti-RPA32 (A300-244A, Bethyl Laboratories Inc.), anti-phospho-RPA32 (S4+S8) (ab87277, Abcam), anti-CHK2 (H300, sc9064, Santa Cruz Biotechnology Inc.), and anti-phospho-CHK2 (ABE343, Millipore) antibodies were used. Secondary peroxidase-conjugated antibody (GE Healthcare) and ECL Western blotting

substrate (Pierce) were used. Anti- $\alpha$ -tubulin or GAPDH antibodies (Santa Cruz Biotechnology Inc.) were used for normalization.

**Transient transfection.** The C-terminal Flag-tagged pCMV6 empty vector and the human *GINS1* expression vector were purchased from OriGene (RC203049). Other constructs were generated by direct mutagenesis with fusion *Taq* from Finnzymes. We transiently transfected HEK293T cells by the calcium phosphate method (Invitrogen).

**Immunoprecipitation assay.** HeLa cells were transiently transfected with pIRESpuroHF-Psf1 (WT or mutants). *GINS1* exon 2 starts at the first amino acid of helix2. We constructed a plasmid for expression of the *GINS1*  $\Delta$ E1 mutant by inserting a Kozak sequence and a start codon (ATG) immediately in front of helix 2. After 48 hours of transfection, cells were harvested and lysed as described previously (48). The lysate was sonicated and treated with Benzonase (Novagen; final concentration, 1.25 U/l) at 4°C for 2 hours, followed by centrifugation at 15,000 *g* for 10 minutes. The supernatant (~640  $\mu$ g protein) was mixed with anti-Flag M2 agarose beads in the presence (+Flag) or absence (-F) of 1 mg/ml 3XFlag peptide and incubated overnight. The beads were then washed 3 times, and the bound proteins were eluted in 1× SDS buffer.

**CMG complex purification.** Sf9 insect cells were co-infected with viruses expressing the 11 CMG subunits, including CDC45 with an HF tag and *GINS4* with a GST tag. After 60 hours of infection, the CMG complexes were purified, as previously described (48). Gradient fractions were subjected to SDS-PAGE separation followed by silver staining.

**ATPase assay.** Reactions were performed as described previously (48). Aliquots (1  $\mu$ l) were spotted onto a polyethylenimine-cellulose TLC plate (Merck) and developed in 0.5 M LiCl/1.0 M formic acid, and products were analyzed using a PhosphorImager (Fujifilm).

**Preparation of a DNA substrate and helicase assay.** M13 DNA helicase substrate was prepared, and helicase assays were carried out as described previously (48). The resolved DNA products were quantified using a PhosphorImager.

**Growth curve and apoptosis rate in primary fibroblasts.** Primary fibroblasts from 5 healthy controls and patients were seed at  $25 \times 10^3$  total cells in a 12-wells plate. Cells were cultured and harvested at the following time points: 1, 3, 6, and 9 days. Total cell numbers and viability rate were assessed with trypan blue using the Vi-CELL-XR Cell Viability Analyzer (Beckman Coulter). The experiment was done twice. Growth curve represents the mean and SD of all controls, and each patient.

**Nuclear analysis.** Primary fibroblasts were fixed by incubation in 3.7% PFA for 10 minutes. The slides were washed and mounted in DAPI-containing mounting medium (Life Technologies). Images were acquired with a fluorescence microscope (Leica, DMR), and the area covered by the nuclei was measured with ImageJ software (NIH).

**Senescence assay.**  $\beta$ -gal staining was performed with a Senescence  $\beta$ -Galactosidase Staining Kit (9860, Cell Signaling Technology). The E6/E7-fibroblasts from 3 different controls and from patients were left untreated or were treated with HU (2 mM) or H<sub>2</sub>O<sub>2</sub> (120  $\mu$ M) for 20 hours; 300 cells were analyzed by microscopy. Three independent experiments were carried out.

**Cell cycle analysis.** Cells were plated at a density of  $1 \times 10^5$  cells/ml, pulse labeled with BrdU for 30 minutes, and washed with PBS. Cells were fixed with methanol and stained with anti-BrdU-FITC antibody (BD Biosciences) and propidium iodide. Flow cytometry analysis was carried out with the BD LSRII flow cytometry system and BD FACSDiva software.

**Nocodazole synchronization.** Cells were plated at a density of  $1.5 \times 10^6$  cells/ml overnight and subsequently treated with nocodazole for 24 hours at a final concentration of 200 ng/ml. Cells were collected after mitotic shake-off, washed twice, and re-plated in a 48-well plate. The cell cycle analysis was done at different time points (0, 4, 8, 12, 16, 20, and 24 hours).

**Immunofluorescence.** E6/E7-fibroblasts were fixed with 3.7% PFA for 10 minutes and permeabilized with 0.5% NP-40 for 10 minutes. Anti- $\gamma$ H2AX (05-636-I, Millipore) and anti-53BP1 (NB100-304, Novus Biological) antibodies were used. The slides were washed and mounted in DAPI-containing mounting medium (Life Technologies).

**DNA replication monitoring by molecular combing.** Cells were labeled as described previously (32). Cells were harvested and embedded in low-melting-point agarose plugs. DNA was subjected to deproteinization with proteinase K. Agarose was removed with agarase, and the high-molecular-weight DNA was used for combing, as previously described. Data analysis was performed as described (33).

**Stable transduction.** cDNAs were delivered using lentiviral transduction after packaging in HEK293T cells. Fibroblasts were transduced in the presence of Polybrene (4 mg/ml) and selected in blasticidin.

**Numerations and functional analysis of ILCs.** Lymphocyte populations were quantified with 6-Color BD Multitest and BD Trucount Technologies. Whole blood was stained with fluorochrome-conjugated mAbs against CD45, CD3, and CD56 and analyzed with a BD FACSCanto II. NK cells were defined as CD3<sup>+</sup>CD56<sup>+</sup> cells in the lymphocyte gate. PBMCs were used to numerate ILC subsets and to perform functional analysis of NK cells. ILCs are defined as lineage-negative and CD127-positive cells within the CD45<sup>+</sup> lymphocyte gate. The lineage contains a mix of FITC-conjugated antibodies against: CD3 (clone UCHT1, BD Pharmingen), CD19 (clone HIB19, BD Pharmingen), CD14 (clone M5E2, BD Pharmingen), CD16 (clone 3G8, BD Pharmingen), CD94 (clone HP-3D9, BD Pharmingen), CD123 (clone 7G3, BD Pharmingen), CD34 (581/CD34, BD Pharmingen), CD303 (clone AC144, Miltenyi Biotec), Fc $\epsilon$ RI (clone AER37, eBioscience). Within the ILC gate, ILC2 are CD294<sup>+</sup> cells, while ILC1 and ILC3 are CD294<sup>+</sup>CD117<sup>-</sup> and CD294<sup>+</sup>CD117<sup>+</sup> cells, respectively. The CD127 (clone HIL-7R-M21), CD117 (clone YB5.B8), and CD294 (clone BM16) antibodies were from BD Pharmingen. Numeration of ILCs was performed with a BD-Fortessa cytometer. For NK cell expansion, PBMCs were incubated for 3.5 days with or without stimulation by IL-2 (100 U/ml) or IL-15 (10 ng/ml). Then, cell surface staining with CD45, CD3, CD56, and CD16 was performed prior to 7-AAD staining. NK cell expansion was evaluated as the percentage of 7-AAD<sup>-</sup>CD3<sup>+</sup>CD56<sup>+</sup> cells within the lymphocyte gate.

**Identification of human T and B lymphoid cells by flow cytometry.** Frozen PBMCs were incubated with mAbs to CD4 (APC-Cy7, clone RPA-T4, BD), CD45RA (FITC, clone HI100, eBioscience), CD127 (BV650, clone A019D5, BioLegend), CD25 (Pe-Cy7, clone 2A3, BD), CXCR5 (A647, clone RF8B2, BD), CXCR3 (BV421, clone G025H7, BioLegend), and CCR6 (BV605, clone G034E3, BioLegend), and proportions of Tregs (CD4<sup>+</sup>CD127<sup>lo</sup>CD25<sup>hi</sup>), total memory cells (CD4<sup>+</sup>CD45RA<sup>-</sup>), and cT<sub>HH</sub> cells (CD4<sup>+</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>), as well as subsets of non-cT<sub>HH</sub> memory and cT<sub>HH</sub> cells defined according to CXCR3 and CCR6 expression, were determined (47). Frozen PBMCs were incubated with mAbs to CD3 (BV421, clone UCHT1, BD), and the frequency of MAIT (CD3<sup>+</sup>CD161<sup>+</sup>V $\alpha$ 7.2<sup>+</sup>), NKT (CD3<sup>+</sup>V $\alpha$ 24<sup>+</sup>V $\beta$ 11<sup>+</sup>), and gamma-delta (CD3<sup>+</sup> $\gamma$  $\delta$ TCR<sup>+</sup>) T cells was determined; the following antibodies were used: V $\alpha$ 24 (FITC, clone C15, Beckman Coulter), V $\beta$ 11

(PE, clone C21, Beckman Coulter), V $\alpha$ 7.2 (APC, clone 3C10, BioLegend), CD161 (PerCP-Cy5.5, clone HP-3G10, eBioscience), and  $\gamma$  $\delta$ TCR (biotin, clone B1, BioLegend). Frozen PBMCs were incubated with mAbs to CD20 (FITC, clone L27, BD), CD27 (Pe-Cy7, clone M-T271, BD), and CD10 (APC, clone HI10a, BD), and the frequency of naive (CD20<sup>+</sup>CD27<sup>-</sup>CD10<sup>-</sup>), transitional (CD20<sup>+</sup>CD27<sup>+</sup>CD10<sup>+</sup>), and memory (CD20<sup>+</sup>CD27<sup>+</sup>CD10<sup>-</sup>) B cells was determined (49).

**Human myeloid cell sorting by flow cytometry.** Frozen PBMCs were stained with fluorochrome-conjugated mAbs against CLEC9a (Vio-Blue, clone 8F9, Miltenyi Biotec), CD1c (FITC, clone AD5-8<sup>E7</sup>, Miltenyi Biotec), CD15 (PE, clone VIMC6, Miltenyi Biotec), CD303 (APC, clone AC144, Miltenyi Biotec); CD16 (V500, clone 3G8, BD Horizon); CD3 (PE, clone UCHT1, BD Pharmingen), CD56 (PE, clone MY31, BD), HLA-DR (PE-Cy7, clone G46-6, BD Pharmingen), CD11c (Alexa Flour 700, clone B-ly6, BD Pharmingen); CD19 (PE, clone J3-119, Beckman Coulter), NKp46 (PE, clone BAB281, Beckman Coulter); CD141 (PerCP 5.5, clone M80, BioLegend), CD14 (APC-Cy7, clone M5E2, BioLegend) and sorted with an Aria II flow cytometer (BD).

**Dihydrorhodamine 123 assay.** Peripheral leukocytes were activated by incubation with various concentrations of PMA for 10 minutes and then incubated for 5 minutes at 37°C with dihydrorhodamine 123 (DHR 123; Sigma-Aldrich) in the presence of catalase (1,300 IU/ml; Sigma-Aldrich). Neutrophil events ( $1 \times 10^4$ ) were recorded by flow cytometry on a FACScan or FACSCanto II machine (Becton Dickinson).

**Statistics.** The mean values of the various measurements (such as nucleus size and replication forks kinetic) were compared between controls and patients, with 1-way ANOVA tests implemented in R software (<http://www.r-project.org/>; version 2.7.1). A *P* value less than 0.05 was considered significant.

**Study approval.** The experiments described here were conducted in accordance with local, national, and international regulations and were approved by the French Ethics committee (ID-RCB: 2010-A00634-35) and by the IRB of Oxford Gastrointestinal Illness (GI) Biobank (REC 11/YH/0020). Informed consent was obtained from all patients or their families, in accordance with the Declaration of Helsinki and European Union directives.

**Sequence data.** The raw sequence data are available on the Sequence Read Archive (SRA) database: Bioproject SRP098828.

## Author contributions

JC, MCK, FPL, YHK, and FV designed the research, performed experiments, and analyzed the data; EKD, TL, LG, YW, AF, MC, LL, CP, and CSM performed the experiments and analyzed the data; PN, AB, YI, BB, FJH, CP, JB, CE, SB, NA, DL, PB, WQ, JAH, AJP, HHU, CF, JM, VPB, LA, JPV, FG, and SGT provided key expertise, reagents, or samples. JH, EV, JLC, AS, and EJ devised the concept, designed the research, supervised the study, and wrote the manuscript, with the help of the other co-authors.

## Acknowledgments

We thank the patients and their families for their participation in this study. We thank the Fondation Jean Dausset-CEPH for the CEPH panel and GenomicVision for technical assistance. JC and EJ thank Patrick Revy, Claire Soudais, and Valérie Cormier-Daire for helpful discussions. We thank Laurent Pradeaux, Thierry Lamireau, Bruno Mortemousque, Abraham Feron, Yves Perel, Marguerite Micheau, and Jean-François Moreau of Bordeaux Hos-

pital. We thank the members of both branches of Human Genetics of Infectious Diseases, especially Anne Puel, Aurélie Cobat, Alexandre Alcaïs, Stéphanie Boisson-Dupuis, Michael Ciancanelli, Vivien Beziat, and Sarah Jill de Jong, for helpful discussions and critical reading of the manuscript; and Lahouari Amar, Dominick Papandrea, Yelena Nemirovskaya, Eric Anderson, Martine Courat, and Michaëla Corrias for secretarial assistance. This work was supported by grants from INSERM, Paris Descartes University, the French National Research Agency (ANR) under the “Investments for the future” program (ANR-10-IAHU-01) and NKD (ANR-15-CE15-0013-01), the Rockefeller University, and the St. Giles Foundation. JC was supported by the Imagine Institute, and YW was supported by the Agence Nationale de la Recherche sur le SIDA et les hépatites (ANRS). LG was supported by a La Ligue Nationale Contre le Cancer (LNCC) grant and by INSERM. MCK was sponsored by an American Cancer Society J.T. Tai postdoctoral fellowship. WQ is supported by Great Ormond Street Hospital Biomedical Research Center and the National Institute of Health Research (RP-2014-05-007). HHU was supported by the Crohn’s & Colitis Foundation of America (CCFA) and the Leona M. and Harry B. Helmsley Charitable Trust. Work in the HHU laboratory was supported by Oxford GI Biobank (Gastrointestinal Illness in Oxford,

REC 11/YH/0020, supported by BRC). Work in the AS laboratory was supported by Rockefeller University, NIH R01HL120922 and 8UL1TR000043 from the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program. AS is a Howard Hughes Medical Institute Faculty Scholar. The laboratory of EV was supported by the European Research Council (THINK Advanced Grant), by the Institut Universitaire de France, and by institutional grants from INSERM, CNRS, and Aix-Marseille University to the CIML. EKD, CSM, and SGT were supported by fellowships and grants from the National Health and Medical Research Council (NHMRC) of Australia (APP1042925, APP1008820, and APP1016953)

Address correspondence to: Jean-Laurent Casanova, Rockefeller University 1230 York Avenue, New York, New York 10065, USA. Phone: 212.327.7332; E-mail: casanova@rockefeller.edu.

CE’s present address is: Department of Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California, USA.

TL and FG’s present address is: Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

- Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. *EMBO J*. 2004;23(2):255–259.
- Vivier E, et al. Innate or adaptive immunity? The example of natural killer cells. *Science*. 2011;331(6013):44–49.
- Jouanguy E, Gineau L, Cottineau J, Béziat V, Vivier E, Casanova JL. Inborn errors of the development of human natural killer cells. *Curr Opin Allergy Clin Immunol*. 2013;13(6):589–595.
- Orange JS. Natural killer cell deficiency. *J Allergy Clin Immunol*. 2013;132(3):515–525.
- Gineau L, et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. *J Clin Invest*. 2012;122(3):821–832.
- Hughes CR, et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. *J Clin Invest*. 2012;122(3):814–820.
- Casanova JL, Abel L, Quintana-Murci L. Immunology taught by human genetics. *Cold Spring Harb Symp Quant Biol*. 2013;78:157–172.
- Bernard F, et al. A novel developmental and immunodeficiency syndrome associated with intrauterine growth retardation and a lack of natural killer cells. *Pediatrics*. 2004;113(1 Pt 1):136–141.
- Eidenschenk C, et al. Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. *J Immunol*. 2006;177(12):8835–8843.
- Conley ME, Casanova JL. Discovery of single-gene inborn errors of immunity by next generation sequencing. *Curr Opin Immunol*. 2014;30:17–23.
- Aparicio T, Ibarra A, Méndez J. Cdc45-MCM-GINS, a new power player for DNA replication. *Cell Div*. 2006;1:18.
- Gambus A, et al. GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. *Nat Cell Biol*. 2006;8(4):358–366.
- Ilves I, Petojevic T, Pesavento JJ, Botchan MR. Activation of the MCM2-7 helicase by association with Cdc45 and GINS proteins. *Mol Cell*. 2010;37(2):247–258.
- Remus D, Diffley JF. Eukaryotic DNA replication control: lock and load, then fire. *Curr Opin Cell Biol*. 2009;21(6):771–777.
- Bell SP, Dutta A. DNA replication in eukaryotic cells. *Annu Rev Biochem*. 2002;71:333–374.
- Masai H, Matsumoto S, You Z, Yoshizawa-Sugata N, Oda M. Eukaryotic chromosome DNA replication: where, when, and how? *Annu Rev Biochem*. 2010;79:89–130.
- Fernández-Cid A, et al. An ORC/Cdc6/MCM2-7 complex is formed in a multistep reaction to serve as a platform for MCM double-hexamers assembly. *Mol Cell*. 2013;50(4):577–588.
- Chang YP, Wang G, Bermudez V, Hurwitz J, Chen XS. Crystal structure of the GINS complex and functional insights into its role in DNA replication. *Proc Natl Acad Sci U S A*. 2007;104(31):12685–12690.
- Takayama Y, Kamimura Y, Okawa M, Muramatsu S, Sugino A, Araki H. GINS, a novel multiprotein complex required for chromosomal DNA replication in budding yeast. *Genes Dev*. 2003;17(9):1153–1165.
- Itan Y, et al. The mutation significance cutoff: gene-level thresholds for variant predictions. *Nat Methods*. 2016;13(2):109–110.
- Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014;46(3):310–315.
- Itan Y, et al. The human gene damage index as a gene-level approach to prioritizing exome variants. *Proc Natl Acad Sci U S A*. 2015;112(44):13615–13620.
- Stoletzki N, Eyre-Walker A. Estimation of the neutrality index. *Mol Biol Evol*. 2011;28(1):63–70.
- Ueno M, Itoh M, Kong L, Sugihara K, Asano M, Takakura N. PSF1 is essential for early embryogenesis in mice. *Mol Cell Biol*. 2005;25(23):10528–10532.
- Ueno M, Itoh M, Sugihara K, Asano M, Takakura N. Both alleles of PSF1 are required for maintenance of pool size of immature hematopoietic cells and acute bone marrow regeneration. *Blood*. 2009;113(3):555–562.
- Kamada K, Kubota Y, Arata T, Shindo Y, Hanaka F. Structure of the human GINS complex and its assembly and functional interface in replication initiation. *Nat Struct Mol Biol*. 2007;14(5):388–396.
- Sengupta S, van Deursen F, de Piccoli G, Labib K. Dpb2 integrates the leading-strand DNA polymerase into the eukaryotic replisome. *Curr Biol*. 2013;23(7):543–552.
- Barkley LR, Song IY, Zou Y, Vaziri C. Reduced expression of GINS complex members induces hallmarks of pre-malignancy in primary untransformed human cells. *Cell Cycle*. 2009;8(10):1577–1588.
- Dimiri GP, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci U S A*. 1995;92(20):9363–9367.
- Minocherhomji S, et al. Replication stress activates DNA repair synthesis in mitosis. *Nature*. 2015;528(7581):286–290.
- Yeeles JT, Deegan TD, Janska A, Early A, Diffley JF. Regulated eukaryotic DNA replication origin firing with purified proteins. *Nature*. 2015;519(7544):431–435.
- Bensimon A, Simon A, Chiffaudel A, Croquette V, Heslot F, Bensimon D. Alignment and sensitive detection of DNA by a moving interface. *Science*. 1994;265(5181):2096–2098.

33. Técher H, et al. Replication dynamics: biases and robustness of DNA fiber analysis. *J Mol Biol.* 2013;425(23):4845–4855.
34. Anglana M, Apiou F, Bensimon A, Debatisse M. Dynamics of DNA replication in mammalian somatic cells: nucleotide pool modulates origin choice and interorigin spacing. *Cell.* 2003;114(3):385–394.
35. Courbet S, et al. Replication fork movement sets chromatin loop size and origin choice in mammalian cells. *Nature.* 2008;455(7212):557–560.
36. Shimada K, Pasero P, Gasser SM. ORC and the intra-S-phase checkpoint: a threshold regulates Rad53p activation in S phase. *Genes Dev.* 2002;16(24):3236–3252.
37. Mazouzi A, Velimezi G, Loizou JI. DNA replication stress: causes, resolution and disease. *Exp Cell Res.* 2014;329(1):85–93.
38. Liu S, et al. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress. *Nucleic Acids Res.* 2012;40(21):10780–10794.
39. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. *Science.* 2003;300(5625):1542–1548.
40. Klein C. Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. *Annu Rev Immunol.* 2011;29:399–413.
41. Yu X, et al. The basic leucine zipper transcription factor NFIL3 directs the development of a common innate lymphoid cell precursor. *Elife.* 2014;3:e04406.
42. Colucci F, et al. Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases. *Nat Immunol.* 2002;3(3):288–294.
43. Aifantis I, Mandal M, Sawai K, Ferrando A, Vilimas T. Regulation of T-cell progenitor survival and cell-cycle entry by the pre-T-cell receptor. *Immunol Rev.* 2006;209:159–169.
44. Clark MR, Mandal M, Ochiai K, Singh H. Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. *Nat Rev Immunol.* 2014;14(2):69–80.
45. Karo JM, Schatz DG, Sun JC. The RAG recombinase dictates functional heterogeneity and cellular fitness in natural killer cells. *Cell.* 2014;159(1):94–107.
46. Frugoni F, et al. A novel mutation in the POLE2 gene causing combined immunodeficiency. *J Allergy Clin Immunol.* 2016;137(2):635–638.e1.
47. Thiffault I, et al. A patient with polymerase E1 deficiency (POLE1): clinical features and overlap with DNA breakage/instability syndromes. *BMC Med Genet.* 2015;16:31.
48. Kang YH, Galal WC, Farina A, Tappin I, Hurwitz J. Properties of the human Cdc45/Mcm2-7/GINS helicase complex and its action with DNA polymerase epsilon in rolling circle DNA synthesis. *Proc Natl Acad Sci USA.* 2012;109(16):6042–6047.
49. Ma CS, et al. Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies. *J Allergy Clin Immunol.* 2015;136(4):993–1006.e1.